Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-23
2009-06-30
Morris, Patricia L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S273700
Reexamination Certificate
active
07553857
ABSTRACT:
The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of at least about 85% entantiomeric excess (“e.e.”). In addition, the present invention provides a magnesium salt of S-omeprazole which is substantially free of neutral omeprazole, meaning that the product contains less than about 3% by weight of a-sum of neutral S-omeprazole and neutral omeprazole. Moreover, the S-omeprazole magnesium according to the invention preferably has assay of related substances and degradation products of less than about 0.1 % by weight as determined by high performance liquid chromatography (HPLC).
REFERENCES:
patent: 6369085 (2002-04-01), Cotton et al.
patent: 6713495 (2004-03-01), Sherman
patent: 6894066 (2005-05-01), Sherman
patent: 7169793 (2007-01-01), Reddy et al.
patent: 2003/0212274 (2003-11-01), Vijayaraghavan et al.
patent: 2004/0235903 (2004-11-01), Khanna et al.
patent: 2006/069159 (2006-06-01), None
Chopra et a., “Formulation and, etc.,” Pharmacos, 25 (1981), pp. 39-45.
Caira, “Crystalline Polymorphism, etc.,” Topics in Current Chemistry, 198, Springer Verlag Berlin Heidelberg, 1998, 163-208.
Xu, “Dynamic vapor. etc.,” CA 2003:773170, 2003.
Threifall, “Analysis of Organic Polymorphs A Review” Analyst, 1995, 120, 2435-2460.
Nerurkar et al., “Properties of Solids, etc.,” Transport Processes in Pharmaceutical Systems, NY Marcel Dekker, Inc., 2000, 575-611.
Hawley's Condensed Chemical Dictionary, 13rh ed., NY: John Wiley & Sons, Inc., 1997, 68.
Brittain ed., Polymorphism in Pharmaceutical Sciences, NY: Marcel Dekker, 1999, pp. 1-2, 185-226.
Doelker, enlglish translation of S.T.P. Pharma Pratiques (1999), 9(5), 2999-409, pp. 1-33.
Muzaffar et al., “Polymorphism and Drug, etc.,” J of Pharmacy (Lahore), 1979, 1(1), 59-66.
Jain et al.,“Polymorphism in Pharmacy”, Indian Drugs, 1986, 23(6), 315-329.
Ulicky et al., Comprehensive Dictionary, etc., NY: Prentice Hall, 1992, 21.
Singhal et al., Drug Polymorphism, etc., AAdvanced Drug Delivery Reviews 56 (2004) 335-347.
Xu, “Dynamic vapor, etc.,” J of Zhejiang University of Technology, 31 (4), 2003, 456-459.
Casar Renata Toplak
Mandic Dejan
Savanovic Lidija Vranicar
Lek Pharmaceuticals d.d.
Luedeka Neely & Graham P.C.
Morris Patricia L
LandOfFree
S-omeprazole magnesium does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with S-omeprazole magnesium, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and S-omeprazole magnesium will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4084040